

**Instant Asset
Tax Write Off***

NIOX Vero[®] Return on Investment

NIOX VERO[®] is a point-of-care device for assessing airway inflammation in patients with respiratory problems such as asthma.

NIOX VERO is a further development of NIOX MINO[®], the most widely used device for measuring airway inflammation in clinical practice and clinical studies all over the world.



NUMBER OF TESTS PER WEEK	1 Year Revenue*	5 Year Revenue*
4	\$19,238	\$96,192
8	\$38,476	\$192,384
12	\$57,715	\$288,576

Based on a Scheduled Fee of \$100.20 for Item Number 11507 over 48 weeks per annum.

MEDICARE BENEFITS - FeNO + Spirometry	Scheduled Fee
<p>ITEM NO 11507 MEASUREMENT OF SPIROMETRY:</p> <p>(a) that includes continuous measurement of the relationship between flow and volume during expiration or during expiration and inspiration, performed before and after inhalation of a bronchodilator; and (b) fractional exhaled nitric oxide (FeNO) concentration in exhaled breath; if: (c) the measurement is performed: (i) under the supervision of a specialist or consultant physician; and (ii) with continuous attendance by a respiratory scientist; and (iii) in a respiratory laboratory equipped to perform complex lung function tests; and (d) a permanently recorded tracing and written report is provided; and (e) 3 or more spirometry recordings are performed unless difficult to achieve for clinical reasons; each occasion at which one or more such tests are performed</p> <p>Not applicable to a service associated with a service to which item 11503, 11512 or 22018 applies</p>	<p>FEE: \$100.20</p> <p>BENEFIT: 75% = \$75.15 85% = \$85.20</p>

*The Australian Tax Office advises that business who turnover less than \$50million can outright deduct any purchase up to \$30k excl GST. This ends on 30th June 2020 as per current legislation. We recommend you seek professional tax advice.

Please note the asset must be delivered and ready for use by 30th June 2020.

Experience the Impact With NIOX VERO®

Improved Treatment and Care of Patients

FeNO (Fractional exhaled Nitric Oxide) testing with NIOX VERO offers individualised asthma management that can improve the treatment and care of patients⁽¹⁾. Regular FeNO testing of asthma patients with NIOX®, measures allergic airway inflammation (Th2 driven) and helps to:

- Reveal if the patient will benefit from ICS (Inhaled corticosteroids) treatment⁽²⁾.
- Optimise ICS dose and reduce exacerbations up to 50%^(3,7).
- Detect patient non-adherence to ICS^(3,4,5).
- Aids in diagnosis and helps to identify patients who may benefit from biologics⁽⁶⁾



What NIOX VERO® gives you

Easy to use and quick results

- Designed with patients and health care professionals in mind to ensure best performance
- Can be used both for children and adults (provided patient cooperation)
- Short start-up time
- Quick analysis time, in approximately one minute

Reliable and accurate results

- Internal check of electronics every time at start-up.
- Measurement result obtained only when the patient completes the ATS test procedure correctly
- Good repeatability allows for one measurement only
- Follows ATS/ERS equipment recommendations

Quality assured measurement results you can rely upon

- Trouble free maintenance
- Service and maintenance free device
- 5 years shelf-life and 15 000 measurements
- No calibration required

NIOX VERO STARTER PACKAGE OPTIONS

AE12-2030

NIOX VERO Starter Package 300 - Contains: NIOX VERO Instrument + NIOX VERO Sensor 300 + 300 NIOX VERO filters

AE12-2050

NIOX VERO Starter Package 500 - Contains: NIOX VERO Instrument + NIOX VERO Sensor 500 + 500 NIOX VERO filters

AE12-2090

NIOX VERO Starter Package 1000 - Contains: NIOX VERO Instrument + NIOX VERO Sensor 1000 + 1000 NIOX VERO filters

References: 1. Spahn JD, Malka J, Szefer J. Current application of exhaled nitric oxide in clinical practice. *J Allergy Clin Immunol.* 2016; 138:1296-1298. 2. Dweik RA, Boggs PB, Erzurum SC, et al; on behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med.* 2011;184(5):602-615. 3. Syk J, Malinowski A, Johansson G, et al. Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial. *J Allergy Clin Immunol Pract.* 2013;1(6):639-648. 4. Beck-Ripp J, Griese M, Arenz S, Köring C, Pasqualoni B, Bufler P. Changes of exhaled nitric oxide during steroid treatment of childhood asthma. *Eur Respir J.* 2002;19(6):1015-1019. 5. Smith AD, Cowan JO, Brassett KP, Herbison P, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. *N Engl J Med.* 2005;352(21):2163-2173. 6. Darveaux J, Busse WW. Biologics in asthma—the next step towards personalized treatment. *J Allergy Clin Immunol Pract.* 2015;3(2):152-161. 7. Peirsman EJ, Carvelli TJ, Hage PY, et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. *Pediatr Pulmonol.* 2014;49(7):624-631.